このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effect of Spontaneous Breathing in APRV Mode on Respiratory Physiology of ARDS Patients (SBA-APRV)

A Randomized Controlled Trial Of The Effect Of Spontaneous Breathing In APRV Mode On Respiratory Physiology In Patients With Acute Respiratory Distress Syndrome

This is a single-center, prospective, randomized, three-period crossover physiological study in adult patients with moderate-to-severe acute respiratory distress syndrome (ARDS, PaO₂/FiO₂ ≤150 mmHg). Each enrolled subject will receive all three APRV ventilation conditions in random sequence: low-level spontaneous breathing (spontaneous minute-ventilation proportion 10%-30%), high-level spontaneous breathing (31%-50%), and fully suppressed spontaneous breathing as control. A 30-minute wash-out period is set between each condition to restore unified physiological baseline. Primary outcome is ventilation-perfusion mismatch percentage (mismatch%) measured by Electrical Impedance Tomography (EIT). Secondary outcomes include EIT-derived pulmonary parameters, respiratory mechanics, hemodynamics, diaphragmatic function and safety profiles. Only short-term, reversible ventilator and sedation adjustments will be performed; routine clinical management remains unchanged throughout the trial.

調査の概要

詳細な説明

Acute respiratory distress syndrome (ARDS) is a life-threatening critical respiratory illness characterized by heterogeneous pulmonary injury and severe ventilation-perfusion mismatch. Airway Pressure Release Ventilation (APRV) permits spontaneous breathing throughout the whole respiratory cycle, which may improve regional ventilation-perfusion matching and hemodynamic status. Nevertheless, excessive spontaneous breathing effort may trigger pendelluft phenomenon, augment regional lung strain and precipitate patient-self-inflicted lung injury (P-SILI). To date, the safe intensity range of spontaneous breathing during APRV for moderate-to-severe ARDS patients has not been well defined.

This single-center, randomized 3-period crossover self-controlled physiological trial enrolls ICU adult patients aged 18-80 years, diagnosed with moderate-to-severe ARDS (PaO₂/FiO₂ ≤ 150 mmHg) within 48-hours of invasive mechanical ventilation. After written informed consent obtained from legal surrogates, subjects will first receive a 60-minute baseline ventilation period following ARDSnet low-tidal-volume pressure-control ventilation strategy under deep sedation without spontaneous breathing. Subsequently, every participant will undergo three APRV intervention states in computer-generated random order: Condition A: APRV with low-intensity spontaneous breathing (spontaneous-contributed minute ventilation 10%-30%); Condition B: APRV with high-intensity spontaneous breathing (31%-50%); Condition C: APRV with fully suppressed spontaneous breathing via deep sedation (RASS -4 to -5). Each intervention maintains target spontaneous-breathing intensity for 30-minute stabilization before data collection. A mandatory 30-minute wash-out phase will be implemented between successive interventions to revert subjects back to baseline pressure-control ventilation and sedation status.

Primary endpoint is the comparison of ventilation-perfusion mismatch percentage (mismatch%, calculated as sum of dead-space fraction and shunt fraction) among three states measured by bedside EIT. Secondary endpoints contain multiple EIT quantitative indices, respiratory mechanics parameters (including esophageal-pressure-derived transpulmonary pressure), hemodynamic and right-ventricular function, diaphragmatic ultrasound indices, arterial blood gas variables. Adverse events related to respiratory, circulatory and operational procedures are closely monitored as safety outcomes.

Planned sample size is 14-16 enrolled participants to achieve 12 evaluable subjects completing all three intervention sequences considering dropout rate. All ventilator and sedation modifications are short-term and reversible; standard clinical therapeutic regimens will not be altered except for study-related procedures. After finishing all three intervention periods, ventilator and sedation settings will be returned to clinical team's discretion. Linear mixed-effect models will be applied for statistical analysis of crossover-design data.

研究の種類

介入

入学 (推定)

15

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Xiaojing Zou
  • 電話番号:+86-27-85351606
  • メール:249126734@qq.com

研究場所

    • Hubei
      • Wuhan、Hubei、中国、430022
        • Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • 1. Age ≥18 and ≤80 years old. 2. Diagnosed with moderate-to-severe ARDS according to the 2023 global ARDS definition.

    3. Within 48 hours of invasive mechanical ventilation. After 1-hour low-tidal-volume pressure-controlled ventilation following ARDSnet strategy, arterial blood gas shows PaO₂/FiO₂ ≤ 150 mmHg.

    4. Written informed consent is obtained from the patient or their legal surrogate decision-maker after full explanation of the study by the principal investigator or authorized study physician.

Exclusion Criteria:

  • 1. Refractory shock defined as persistent hyperlactatemia and/or prolonged capillary refill time, fluid-resistant, requiring norepinephrine ≥ 0.5 μg/kg/min.

    2. Severe chronic medical conditions severely affecting cardiopulmonary function: severe chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, right-heart failure, pulmonary hypertension, or severe arrhythmia.

    3. Radiologically confirmed bronchopleural fistula, status post lobectomy, or other major thoracic surgery.

    4. Contraindications to electrical impedance tomography (EIT): extensive chest skin injury or infection, implanted cardiac pacemaker or defibrillator, etc.

    5. Contraindications for esophageal manometry placement: esophageal obstruction, perforation, severe esophageal varices, etc.

    6. Diaphragmatic hernia, severe chest wall deformity, or significant pulmonary bullae.

    7. Significant coagulation abnormalities (PT or APTT prolonged ≥2 times upper limit of normal, or INR>2.0) with active bleeding risk.

    8. Severe intracranial hypertension (>20 mmHg), severe traumatic brain injury (GCS ≤8), or neuromuscular disorders.

    9. Pregnant or breastfeeding women. 10. Patients already receiving ECMO therapy. 11. Expected survival time <24 hours judged by attending physician. 12. Body mass index (BMI) >35 kg/m². 13. Previously enrolled in this study or participating in other interventional clinical trials.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Low-level spontaneous breathing under APRV
APRV ventilation with spontaneous-contributed minute-ventilation proportion maintained at 10%-30%. A stabilization period of 30 minutes is performed before data collection
APRV ventilation mode, spontaneous-contributed minute-ventilation proportion maintained at 10%-30%. 30-minute stabilization before outcome measurement.
実験的:High-level spontaneous breathing under APRV
APRV ventilation with spontaneous-contributed minute-ventilation proportion maintained at 31%-50%. A stabilization period of 30 minutes is performed before data collection.
APRV ventilation mode, spontaneous-contributed minute-ventilation proportion maintained at 31%-50%. 30-minute stabilization before outcome measurement.
実験的:Fully suppressed spontaneous breathing under APRV
APRV ventilation with spontaneous breathing completely suppressed by deep sedation (RASS-4 to -5). A stabilization period of 30 minutes is performed before data collection.
APRV ventilation mode, spontaneous breathing fully suppressed by deep sedation (RASS-4 to -5). 30-minute stabilization before outcome measurement.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Ventilation-perfusion mismatch percentage (Mismatch%)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Ventilation-perfusion mismatch percentage (Mismatch%), calculated as the sum of dead-space percentage and shunt percentage measured by electrical impedance tomography (EIT). A composite index reflecting overall ventilation-perfusion mismatch, assessed at baseline and under three APRV experimental conditions. Unit: %
Baseline and at the end of each 30-minute experimental condition during the study intervention period.

二次結果の測定

結果測定
メジャーの説明
時間枠
Match percentage(match%)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Match percentage derived from electrical impedance tomography (EIT). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Pendelluft amplitude
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Pendelluft amplitude derived from electrical impedance tomography (EIT). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Dead-space percentage
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Dead-space percentage derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Shunt percentage
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Intrapulmonary shunt percentage derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Global inhomogeneity index (GI)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period
Global inhomogeneity index (GI) derived from electrical impedance tomography (EIT). Unit: unitless.
Baseline and at the end of each 30-minute experimental condition during the study intervention period
Center of ventilation (CoV)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Center of ventilation (CoV) derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Tidal recruitment-derecruitment
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Tidal recruitment-derecruitment (Tidal R/D) derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Ventilation distribution
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Regional ventilation distribution derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Perfusion distribution
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Regional pulmonary perfusion distribution derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Peak airway pressure (Ppeak)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Airway peak pressure (Ppeak) measured by mechanical ventilator, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Plateau pressure (Pplat)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Airway plateau pressure (Pplat) obtained from end-inspiratory hold maneuver, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Driving pressure (ΔP)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Driving pressure (ΔP) derived from mechanical ventilator measurements. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Static respiratory system compliance (Cstat)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Static respiratory system compliance (Cstat), assessed at baseline and under three APRV experimental conditions. Unit: mL/cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-inspiratory esophageal pressure (PesI)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-inspiratory esophageal pressure (PesI) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-expiratory esophageal pressure (PesE)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-expiratory esophageal pressure (PesE) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Esophageal pressure swing (ΔPes)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Esophageal pressure swing (ΔPes) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-inspiratory transpulmonary pressure (PtpI)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-inspiratory transpulmonary pressure (PtpI) derived from airway and esophageal pressure measurements. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Transpulmonary driving pressure (ΔPtp)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Transpulmonary driving pressure (ΔPtp) derived from airway and esophageal pressure measurements. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-expiratory transpulmonary pressure (PtpE)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-expiratory transpulmonary pressure (PtpE) derived from airway and esophageal pressure, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Esophageal pressure-time product per minute (PTPes/min)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Esophageal pressure-time product per minute (PTPes/min) read directly from the ventilator interface. Unit: cmH₂O·s/min.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Dynamic transpulmonary driving pressure (ΔPL,dyn)
時間枠:At the end of each 30-minute APRV experimental condition (after stabilization)
Dynamic transpulmonary driving pressure (ΔPL,dyn) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O.
At the end of each 30-minute APRV experimental condition (after stabilization)
Inspiratory muscle pressure (Pmus)
時間枠:At the end of each 30-minute APRV experimental condition (after stabilization)
Inspiratory muscle pressure (Pmus) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O
At the end of each 30-minute APRV experimental condition (after stabilization)
End-expiratory occlusion pressure (ΔPocc)
時間枠:At the end of each 30-minute APRV experimental condition (after stabilization)
End-expiratory occlusion pressure (ΔPocc) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O
At the end of each 30-minute APRV experimental condition (after stabilization)
Airway occlusion pressure (P0.1)
時間枠:At the end of each 30-minute APRV experimental condition (after stabilization)
Airway occlusion pressure (P0.1) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O
At the end of each 30-minute APRV experimental condition (after stabilization)
Muscular pressure index (PMI)
時間枠:At the end of each 30-minute APRV experimental condition (after stabilization)
Muscular pressure index (PMI) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O
At the end of each 30-minute APRV experimental condition (after stabilization)
Negative inspiratory force (NIF)
時間枠:At the end of each 30-minute APRV experimental condition (after stabilization)
Negative inspiratory force (NIF) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O
At the end of each 30-minute APRV experimental condition (after stabilization)
Heart rate
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Heart rate from continuous bedside monitoring, assessed at baseline and under three APRV experimental conditions. Unit: beats per minute.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Mean arterial pressure (MAP)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Mean arterial pressure (MAP) measured via invasive arterial catheter, assessed at baseline and under three APRV experimental conditions. Unit: mmHg.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Vasopressor dosage (μg/kg/min)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Dosage of vasoactive medications, assessed at baseline and under three APRV experimental conditions. Unit: μg/kg/min
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Central venous pressure (CVP)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Central venous pressure (CVP), assessed at baseline and under three APRV experimental conditions. Unit: mmHg.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Right-ventricular fractional area change
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Right-ventricular fractional area change measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Velocity-time-integral (VTI)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Velocity-time-integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions. Unit: cm.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Tricuspid annular plane systolic excursion (TAPSE)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Tricuspid annular plane systolic excursion (TAPSE) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions. Unit: mm.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Cardiac output (CO)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Cardiac output (CO) calculated from velocity-time integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions. Unit: L/min.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Stroke volume (SV)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Stroke volume (SV) calculated from velocity-time-integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions. Unit: mL.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Diaphragm displacement
時間枠:At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Diaphragm displacement measured by bedside diaphragm ultrasound, assessed in two out of the three APRV experimental conditions only when spontaneous breathing was present. Unit: mm.
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Diaphragm thickening fraction
時間枠:At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Diaphragm thickening fraction measured by bedside diaphragm ultrasound, assessed in two out of the three APRV experimental conditions only when spontaneous breathing was present. Unit: %.
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Lung 12-zone ultrasound score
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Lung ultrasound score based on 12-zone lung ultrasound assessment, assessed at baseline and under three APRV experimental conditions. Unit: unitless.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Overdistension (OD) pixel count
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Pixel count of lung overdistension (OD), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: pixels.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Overdistension (OD) proportion
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Proportion of lung overdistension (OD) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Recruitment (CR) pixel count
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Pixel count of lung recruitment (CR), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: pixels.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Recruitment (CR) proportion
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Proportion of lung recruitment (CR) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Atelectasis (AT) pixel count
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Pixel count of lung atelectasis (AT), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: pixels.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Atelectasis (AT) proportion
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Proportion of lung atelectasis (AT) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.

その他の成果指標

結果測定
メジャーの説明
時間枠
Incidence and severity of adverse events
時間枠:During each APRV experimental intervention period
Incidence and severity of adverse events during study interventions, focusing on respiratory events, circulatory events and procedure-related adverse events. Unit: unitless.
During each APRV experimental intervention period
Rate of premature intervention discontinuation for safety concerns
時間枠:During each APRV experimental intervention period
Rate of premature discontinuation of study interventions due to safety-related reasons. Unit: %.
During each APRV experimental intervention period
Inspired oxygen fraction (FiO₂)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Set inspired oxygen fraction, obtained directly from ventilator readings, recorded at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial pH
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial blood pH measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: unitless.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial partial pressure of oxygen (PaO₂)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial partial pressure of oxygen measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmHg.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial partial pressure of carbon dioxide (PaCO₂)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial partial pressure of carbon dioxide measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmHg.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial oxygen saturation (SaO₂)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial oxygen saturation measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Bicarbonate (HCO₃-)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Serum bicarbonate (HCO₃-) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmol/L.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Base excess (BE)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Base excess (BE) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmol/L.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial lactate (Lac)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial lactate (Lac) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmol/L.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
PaO₂/FiO₂ ratio
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
PaO₂/FiO₂ ratio calculated from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: unitless.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Alveolar-arterial oxygen difference (A-aDO₂)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Alveolar-arterial oxygen difference calculated from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmHg.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Correlation analysis among multiple respiratory-hemodynamic-diaphragm parameters
時間枠:Corresponding study time points
Explore the correlations among EIT parameters, respiratory mechanics, blood gas analysis, hemodynamics and diaphragm function across three study conditions.
Corresponding study time points
Ventilatory ratio (VR)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Ventilatory ratio (VR), a calculated index reflecting pulmonary dead-space and lung injury severity, is computed from minute ventilation and arterial CO₂ values assessed at baseline and under three APRV experimental conditions. Unit: unitless.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Expired tidal volume (VTe)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Expired tidal volume assessed at baseline and under three APRV experimental conditions. Unit: mL.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Total respiratory rate
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Total respiratory rate assessed at baseline and under three APRV experimental conditions. Unit: breaths/min.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Total minute ventilation
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Total minute ventilation assessed at baseline and under three APRV experimental conditions. Unit: L/min.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Spontaneous minute ventilation
時間枠:At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Spontaneous component of minute ventilation assessed under two APRV experimental conditions only when spontaneous breathing was present, derived directly from ventilator readings. Unit: L/min.
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Proportion of spontaneous minute ventilation
時間枠:At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Proportion of spontaneous minute ventilation relative to total minute ventilation, calculated under two APRV experimental conditions only when spontaneous breathing was present. Unit: %.
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Mechanical power (MP)
時間枠:Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Mechanical power of ventilation as an indicator of ventilator-induced lung injury (VILI) risk, obtained directly from ventilator readings at baseline and under three APRV experimental conditions. Unit: J/min.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:xiaojing zou, MD、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2026年11月1日

研究の完了 (推定)

2026年12月1日

試験登録日

最初に提出

2026年8月20日

QC基準を満たした最初の提出物

2026年8月27日

最初の投稿 (実際)

2026年9月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月1日

QC基準を満たした最後の更新が送信されました

2026年8月27日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • PROTO-APRV-2026-01
  • MR-42-26-065895 (その他の識別子:National Medical Research Registration and Filing Information System of China)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する